ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
Julia Hofmann
Head of Corporate Communications
Phone: +49 89 329 8986 1500
